CA Patent

CA2220358A1 — Transdermal therapeutic system (tts) for the administration of testosterone

Assigned to Hexal AG · Expires 1996-11-14 · 30y expired

What this patent protects

The invention concerns a transdermal therapeutic system for administering testosterone or a testosterone derivative as the active substance.

USPTO Abstract

The invention concerns a transdermal therapeutic system for administering testosterone or a testosterone derivative as the active substance.

Drugs covered by this patent

Patent Metadata

Patent number
CA2220358A1
Jurisdiction
CA
Classification
—
Expires
1996-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Hexal AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.